Efficacy of triple antiplatelet therapy in patients with diabetes mellitus combined with coronary he

• 作 者: Li Shihong Yan Dong Chen Xunzu Lin Yun Zhang Jingmei Li Zhizhong
• 机 构: department of Cardiology,Beijing Anzhen Hospital,Capital Medical University,Beijing100029,China
• 出 处: 第八届北京五洲国际心血管病会议
• 发表日期: 2014年12期
• 关键词: coronary heart disease PCI anti platelet therapy cilostazol

　　Objective To observe diabetic patients after percutaneous coronary intervention (PCI) in the prevention of stent restenosis, prevention of in stent restenosis, clinical efficacy and safety of aspirin, clopidogrel and cilostazol antiplatelet therapy.Methods 166 patients with coronary heart disease (CHD)-double transmitte grouped into control group (80 cases) and treatment group-three transmitte (86 cases) and control group 100 mg/d of aspirin, clopidogrel 75 mg/d.Treatment group on the basis of the double helo he thiazole, 100 mg/d record analysis of baseline data of two groups, the difference of the result of coronary angiography and PCI, two groups were followed for the primary end point and the difference of incidence of secondary end point index.Results Two groups of clinical baseline data, coronary angiography and PCI there was no statistically significant difference results.Minimal lumen diameter of treatment group was obviously higher than that of control group (2.76±0.53 mm vs 1.35±0.32 mm, P<0.05); Treatment group late lumen loss, restenosis rate were significantly lower than the control group (1.28± 0.33 mm vs0.71 ±0.23mm, P<0.05).1 months and 12 months follow-up individualized treatment of the primary end point index significantly lower incidence of standardized treatment, the difference was statistically significant (1 month: 2.3% vs 8.7%, P < 0.05; 1 year: 5.8% vs 11.2%, P < 0.05); The incidence of secondary end points are no statistically significant difference (1 month: 1.16% to 1.25%; 1 year: 2.3% vs 2.5%, P > 0.05).Conclusion PCI postoperative prevention of in stent restenosis in patients with clopidogre175 mg/d, aspirin 100 mg/d and 100 mg/d of cilostazol, is safe dose, medication of patients with coronary artery disease after PCI curative effect, can further reduce major adverse cardiovascular event rates, at the same time does not increase the risk of bleeding.